XERS | Ticker Profile - Titan Protect

XERS

Xeris Biopharma Holdings, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NMS

$6.18

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.1B

Total market value of the company

Trailing P/E

89.00

Expensive — high growth expected

Forward P/E

15.77

Based on estimated future earnings — lower means cheaper

Rev Growth

+38.3%

Year-over-year revenue change

Profit Margin

3.8%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+62% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

https://www.xerispharma.com

Country: United States Employees: 435 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.335

Excellent risk-adjusted returns

Kelly Fraction

0.0684

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.752

Returns exceed worst-case losses — strong risk profile

Annual Return

81.6%

Historical annualised return based on price data

Max Drawdown

-46.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.92

Less volatile than the market — more defensive

52W High

$10.08

39% below the year high

52W Low

$4.30

44% above the year low

Avg Volume

1,754,831

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

7.4%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.07

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1,987.19

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.12

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.42

Like current ratio but excludes inventory — stricter test

Gross Margin

85.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

9.5%

Profit from core operations before interest and tax

Free Cash Flow

$42M

Positive — the business generates more cash than it spends

Revenue (TTM)

$315M

Total revenue over the last 12 months

Net Income

$12M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$10.00

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go